Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants

  • Immunome Inc (NASDAQ:IMNM) has announced that its cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in lab testing. 
  • IMM-BCP-01 is currently in Phase 1b testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5, and BA.2.
  • Related: Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data.
  • The company expects topline data from Phase 1b study in 2H of 2022.
  • IMM-BCP-01 is a three-antibody cocktail, with each antibody having a different mechanism of action. 
  • "Further, as several existing antibody treatments lose their potency against the Omicron subvariants, IMM-BCP-01 continues to retain activity against these variants in preclinical testing, and we believe our cocktail has the potential to play a significant role in managing the pandemic," stated Purnanand Sarma, President & CEO.
  • Price Action: IMNM shares closed at $3.42 on Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.